← Back to Search

Other

Cohort 3 for Dyslipidemia

Phase 1
Waitlist Available
Research Sponsored by Esperion Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 or 28 days
Awards & highlights

Summary

This Phase 1, double-blind (sponsor open) study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 given to subjects with mild dyslipidemia.

Eligible Conditions
  • Dyslipidemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 or 28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 or 28 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Characterization of pharmacokinetic parameters and percent change from baseline in pharmacodynamic endpoints

Side effects data

From 2018 Phase 3 trial • 269 Patients • NCT03001076
8%
Blood uric acid increase
4%
Headache
4%
Liver function test increased
3%
Urinary tract infection
3%
Nausea
3%
Muscle spasms
3%
Sinusitis
2%
Nasopharyngitis
2%
Myalgia
2%
Glomerular filtration rate decreased
1%
Osteoarthritis
1%
Hepatic cancer
1%
Syncope
1%
Dysuria
1%
Intestinal obstruction
1%
Diabetes mellitus
1%
Bronchitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Bempedoic Acid

Trial Design

5Treatment groups
Experimental Treatment
Group I: Cohort 5Experimental Treatment1 Intervention
Free-living subjects (18 active/6 placebo) with mild dyslipidemia
Group II: Cohort 4Experimental Treatment1 Intervention
Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
Group III: Cohort 3Experimental Treatment1 Intervention
Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
Group IV: Cohort 2Experimental Treatment1 Intervention
Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
Group V: Cohort 1Experimental Treatment1 Intervention
Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ETC-1002 or placebo
2010
Completed Phase 1
~60

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Esperion Therapeutics, Inc.Lead Sponsor
25 Previous Clinical Trials
21,865 Total Patients Enrolled
1 Trials studying Dyslipidemia
177 Patients Enrolled for Dyslipidemia
Jim C Khalifa, MDStudy DirectorEsperion Therapeutics, Inc.
~3 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top